
Novo Nordisk A/S Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 92 trades in Novo Nordisk A/S (NYSE: NVO) since 2014, across 21 members, worth an estimated $2.5M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 54 buys against 38 sells, a modestly buy-led skew, with Democratic members responsible for 22% of the trades and Republican members 78%. The most recent disclosure shown was filed September 2026, and Kevin Hern has filed the most NVO transactions among those shown, with 2. Other recent filers include Scott Scott Franklin, Alan Armstrong, and Rohit Khanna. One notable disclosed move was a purchase by Rohit Khanna on February 13, 2026, down 17.5% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Novo Nordisk A/S's current Quantellect Tide Score is 68 out of 100 (High Tide), Top 10% of universe (3865); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Novo Nordisk A/S (NVO) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Novo Nordisk A/S congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
![]() Kevin Hern House | Sep 25, 2026 | Sep 10, 2026 | 15 days | Sell | $1,001 - $15,000 | -10.41% | Self | |
![]() Kevin Hern House | Sep 25, 2026 | Aug 31, 2026 | 25 days | Sell | $1,001 - $15,000 | -13.02% | Self | |
![]() Scott Scott Franklin House | Sep 17, 2026 | Aug 26, 2026 | 22 days | Buy | $1,001 - $15,000 | -16.44% | Self | |
![]() Alan Armstrong Senate | Jul 21, 2026 | Mar 30, 2026 | 113 days | Buy | $15,001 - $50,000 | +11.73% | Self | |
![]() Rohit Khanna House | Apr 7, 2026 | Mar 13, 2026 | 25 days | Buy | $1,001 - $15,000 | +7.68% | Spouse | |
![]() Rohit Khanna House | Mar 9, 2026 | Feb 13, 2026 | 24 days | Buy | $1,001 - $15,000 | -17.54% | Spouse |
Novo Nordisk A/S (NVO) congressional trading FAQ
Can members of Congress legally trade Novo Nordisk A/S (NVO) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Novo Nordisk A/S (NVO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Novo Nordisk A/S (NVO) trades public?
Yes. Every congressional trade in Novo Nordisk A/S (NVO) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Novo Nordisk A/S (NVO)?
Members of Congress have disclosed 92 trades in Novo Nordisk A/S (NVO) worth $2.5M across 21 members, according to public STOCK Act filings.
Which members of Congress have traded Novo Nordisk A/S (NVO)?
Recent and active filers of Novo Nordisk A/S (NVO) disclosures include Kevin Hern, Rohit Khanna, Scott Scott Franklin. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Novo Nordisk A/S (NVO) more?
Across disclosed Novo Nordisk A/S (NVO) trades, 22% were by Democrats and 78% by Republicans, led by Republicans (78%).
What is the most recent congressional Novo Nordisk A/S (NVO) trade?
The most recent disclosed Novo Nordisk A/S (NVO) filing reported a sell by Kevin Hern, filed Sep 24, 2026.
What is Novo Nordisk A/S (NVO)'s Tide Score?
Novo Nordisk A/S (NVO) has a Quantellect Tide Score of 68 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.
Browse all stocks Congress tradesCongressional trading overviewNovo Nordisk A/S (NVO) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.





